Beuth J - Search Results

1

Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.

Heiny BM, Beuth J. Heiny BM, et al. Among authors: beuth j. Anticancer Res. 1994 May-Jun;14(3B):1339-42. Anticancer Res. 1994. PMID: 8067703

2

Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study.

Beuth J, Schneider B, Schierholz JM. Beuth J, et al. Anticancer Res. 2008 Jan-Feb;28(1B):523-7. Anticancer Res. 2008. PMID: 18383896

3

Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model.

Beuth J, Ko HL, Schneider H, Tawadros S, Kasper HU, Zimst H, Schierholz JM. Beuth J, et al. Anticancer Res. 2006 Nov-Dec;26(6B):4451-6. Anticancer Res. 2006. PMID: 17201168

4

Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy.

Klopp R, Schmidt W, Werner E, Werner M, Niemer W, Beuth J. Klopp R, et al. Among authors: beuth j. Anticancer Res. 2005 Jan-Feb;25(1B):601-10. Anticancer Res. 2005. PMID: 15816634 Clinical Trial.

5

Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study.

Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J. Schumacher K, et al. Among authors: beuth j. Anticancer Res. 2003 Nov-Dec;23(6D):5081-7. Anticancer Res. 2003. PMID: 14981970 Clinical Trial.

6

Changes in immunological characteristics of white blood cells after administration of standardized mistletoe extract.

Klopp R, Schmidt W, Niemer W, Werner M, Beuth J. Klopp R, et al. Among authors: beuth j. In Vivo. 2001 Nov-Dec;15(6):447-57. In Vivo. 2001. PMID: 11887328

7

Cytokine release of whole blood from adult female donors challenged with mistletoe lectin-1 standardised mistletoe extract and E. coli endotoxin or phytohaemagglutinin (PHA).

Braun JM, Blackwell CC, Weir DM, Beuth J. Braun JM, et al. Among authors: beuth j. Anticancer Res. 2003 Mar-Apr;23(2B):1349-52. Anticancer Res. 2003. PMID: 12820393

8

Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.

Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Piao BK, et al. Among authors: beuth j. Anticancer Res. 2004 Jan-Feb;24(1):303-9. Anticancer Res. 2004. PMID: 15015612 Clinical Trial.

9

Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe.

Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J. Lenartz D, et al. Among authors: beuth j. Anticancer Res. 2000 May-Jun;20(3B):2073-6. Anticancer Res. 2000. PMID: 10928154 Clinical Trial.

10

Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.

Schaffrath B, Mengs U, Schwarz T, Hilgers RD, Beuth J, Möckel B, Lentzen H, Gerstmayer B. Schaffrath B, et al. Among authors: beuth j. Anticancer Res. 2001 Nov-Dec;21(6A):3981-7. Anticancer Res. 2001. PMID: 11911280

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results